welcome

 

AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life.

We believe that OMIC technologies represent an important first step towards gaining biological insights into:

  • How drugs work, giving them added value, reducing attrition rates and advancing  through the clinic.
  • Determining clinically predictive molecular endpoints that help physicians manage the disease, drive prescriptions and monitor drug response.

latest news and events

 

January 2017

Aromics' CEO Dr. Plasencia, winner of the prize FEM TALENT 2017 for her career path

Dr. Carmen Plasencia, CEO of AROMICS, was recognized today for her career path, being one of the winers...

mas noticias

 

January 2017

Aromics CEO, DR. Plasencia, one of the finalists at the Fem Talent awards

We areĀ  pleased of communicate that Dr. Carme Plasencia, CEO of AROMICS, has been selected as finalist...

mas noticias

 

With 35,000 genes and hundreds of thousands of protein states to identify, correlate, and characterize, the studies of one gene, gene product, or process are no longer reliable or cost-effective. We have entered the "omic" era in biology. But large- scale omic studies of cellular molecules in aggregate rarely answer interesting questions without the assistance of information from traditional hypothesis- driven research. These scientific methods are complementary and synergistic.

John N. Weinstein. Disease Markers 17(2): 77- 88, 2001.